MethylGene Announces the Appointment of Peggy Mulliganto Its Board of Directors
“Peggy is a financial and audit expert, and a well respected business leader. We look forward to her guidance as we plan for the future”, said Charles Grubsztajn, President and CEO of MethylGene.
Peggy most recently served as Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals International, Inc (formerly Biovail Corporation), a multinational pharmaceutical company listed on both the New York Stock Exchange and Toronto Stock Exchange. During her tenure, she co-led the merger and subsequent integration with Valeant Pharmaceuticals International, Inc. She is currently a member of the Board of Directors of Ontario Power Generation Inc. (“OPG”) and Chair of OPG’s Human Resources & Compensation Committee. From 2005 to 2007 Peggy served as Executive Vice President, Chief Financial Officer and Treasurer of Linamar Corporation. Previously Peggy spent eleven years in various roles at the Bank of Nova Scotia, most recently as Executive Vice President, Systems & Operations. Before joining the Bank of Nova Scotia she was an Audit Partner with Price Waterhouse. In 2003 and 2004 Ms. Mulligan was named one of Canada’s Top 100 Most Powerful Women by the Women’s Executive Network. She holds a B. Math (Honours) from the University of Waterloo and she is a Fellow of the Institute of Chartered Accountants (FCA) of Ontario.
About MethylGene
MethylGene Inc. (TSX:MYG) is a small molecule drug development company that is advancing two novel therapeutics for cancer and infectious disease in human clinical trials. The Company’s lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme, that is currently in Phase 2 trials for vulvovaginal candidiasis and MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase 1/2 clinical trials for solid tumor cancers. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.
Investor Relations Contact:
Joseph Walewicz, CFA
Vice President, Business & Corporate Development
MethylGene Inc.
Phone: 514-337-3333 ext. 373
ir@methylgene.com
www.methylgene.com
Thomas Fechtner
Vice President
The Trout Group LLC
Phone: 646-378-2931
tfechtner@troutgroup.com
www.troutgroup.com